Quarter
Charts
πŸ‡ΊπŸ‡ΈUS Markets

MIMEDX GROUP, INC.

MDXG

CIK 0001376339 Β· Quarterly mode Β· latest period FY2025 (Q4) (ending 2025-12-31) Β· sourced from SEC EDGAR

At a glance Β· FY2025 (Q4)

Revenue
$118M
↑+27.1% +$25Mvs FY2024 (Q4)
Operating Income
$21M
↑+90.7% +$10Mvs FY2024 (Q4)
Net Income
$15M
↑+104.2% +$8Mvs FY2024 (Q4)
Gross Profit
$99M
↑+30.3% +$23Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot Β· latest annual filed values Β· S&P 500 calibration

Strong
76/100
  • Profitability
    63ROIC 17.7% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 4.32 (above 1.5 = solid)
  • Leverage
    96D/E 0.07 (under 0.5 = conservative)
  • Efficiency
    82Asset Turnover 1.27x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +27.1% (10% = solid, 25%+ = elite)
  • Margin Trend
    15Op Margin 17.8% Β· trend -2.1pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project MDXG's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

8%

Trailing CAGR unavailable; default 8%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≀ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$8.50
Total enterprise IV
$1.27B
Diluted shares
0.15B
Terminal PV
$923M (72% of total)
Year-5 FCF
$109M
YearProjected FCFDiscounted PV
+1$80M$73M
+2$86M$71M
+3$93M$70M
+4$101M$69M
+5$109M$68M
Terminal$1.49B$923M

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target β€” and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation Β· trailing 4 quarters

how the company spent its cash
Capex (TTM)
β€”
investment in PP&E
Stock buybacks (TTM)
β€”
share count reduction
Stock-based comp (TTM)
$16M
non-cash dilution

Balance sheet Β· 2025-12-31

latest filed snapshot
Total assets
$343M
everything owned
Total liabilities
$86M
everything owed
Stockholders' equity
$257M
shareholder claim
Net debt
$-148M
Net cash position ($148M)

Recent performance Β· 63 quarters

Revenue↑+27.1% +$25M
$118M
Net Income↑+104.2% +$8M
$15M
Free Cash Flow↑+32.9% +$6M
$25M
Operating Margin↑+5.9pts
17.8%

Drill down